Research study to look at how well the drug concizumab works in your body if you have haemophilia with inhibitors

Phase 1

• Conditions: Haemophilia A with inhibitorsHaemophilia B with inhibitors; MedDRA version: 20.0Level: LLTClassification code 10053751Term: Hemophilia A with anti factor VIIISystem Organ Class: 100000004850; MedDRA version: 20.0Level: LLTClassification code 10053752Term: Hemophilia B with anti factor IXSystem Organ Class: 100000004850; Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]

• Registration Number: EUCTR2018-004889-34-SE
• Lead Sponsor: ovo Nordisk A/S

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-07-17
• Last Update Posted: 26 February 2024

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: Male
• Target Recruitment: 136

Inclusion Criteria

- Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial
- Male aged 12 or older years at the time of signing informed consent
- Congenital Haemophilia A or B of any severity with documented history of inhibitor (0.6 BU or more)
- Patient has been prescribed, or in need of, treatment with bypassing agents in the last 24 weeks prior to screening (for patients not previously enrolled in NN7415-4310 (explorer 4))
Are the trial subjects under 18? yes
Number of subjects for this age range: 15
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 96
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 10

Exclusion Criteria

- Known or suspected hypersensitivity to any constituent of the trial product or related products
- Known inherited or acquired coagulation disorder other than congenital haemophilia
- Ongoing or planned Immune Tolerance Induction treatment
- History of thromboembolic disease (includes arterial and venous thrombosis including myocardial infarction, pulmonary embolism,
cerebral infarction/thrombosis, deep vein thrombosis, other clinically significant thromboembolic events and peripheral artery occlusion).
Current clinical signs of, or treatment for thromboembolic disease.
Patients who in the judgement of the investigator are considered at high risk of thromboembolic events (thromboembolic risk factors could
include, but are not limited to, hypercholesterolemia, diabetes mellitus, hypertension, obesity, smoking, family history of thromboembolic
events, arteriosclerosis, other conditions associated with increased risk of thromboembolic events.)

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified